SAN FRANCISCO, Oct. 15, 2025 /PRNewswire/ -- Quintara Biosciences today announced that it has completed the acquisition of Laragen Sanger Sequencing, formerly operated by Transnetyx, effective September 15, 2025. The acquisition ensures uninterrupted service for existing customers while reinforcing Quintara's strategic growth across California's life sciences corridor.

"Transnetyx is happy to see Quintara Biosciences continue the good work of Sanger Sequencing for all the loyal customers in Los Angeles who have been served by Laragen in their research for many years. Quintara's excellent reputation and broad scientific competency will make a trusted partner for all those customers seeking groundbreaking discovery," said Bob Bean, CEO of Transnetyx.

Commitment to Customers

All Sanger Sequencing services previously offered by Laragen, including DNA Sequencing, Microbial Identification, and Cell Line Identification, will continue without disruption. Operations remain in place with the same experienced team, instruments, and convenient drop-box network trusted by customers for years. Quintara will also honor Laragen's existing pricing arrangements to ensure a smooth transition.

Strategic Value for Industry and Partners

Los Angeles is home to some of the nation's premier research centers, including UCLA, Caltech, and City of Hope, making it a critical hub for biomedical discovery. By integrating Laragen's deep market presence with Quintara's broader sequencing and molecular biology capabilities, the acquisition expands Quintara's reach and enhances its ability to meet the growing demand for high-quality, accessible life science services.

"This acquisition reflects our dual commitment to maintain service continuity for researchers while advancing our long-term strategic footprint," said Daniel Wang, CEO of Quintara Biosciences. "Los Angeles has always been a vital link between our Bay Area and San Diego operations. Strengthening our presence here not only connects our California network but also positions us to serve the entire West Coast with faster turnaround, expanded sequencing options, and greater operational resilience."

"From an operational perspective, integrating Laragen Sanger Sequencing Services enhances our throughput and reinforces our local sequencing infrastructure," added Sue Zhao, General Manager of Quintara Biosciences. "It also supports our expansion into long-read and high-throughput sequencing applications, enabling us to provide comprehensive solutions that bridge traditional Sanger workflows with advanced sequencing platforms and molecular biology services."

About Quintara Biosciences

Quintara Biosciences is a leading genomics and molecular biology CRO/CDMO providing comprehensive sequencing and molecular services to the biotech and academic research community. With operations in Boston, MA; San Fransico, CA; San Diego, CA; Los Angeles, CA; and Houston, TX, Quintara specializes in Sanger, NGS, Nanopore, molecular biology, and recombinant antibody/protein production solutions designed to accelerate discovery and development. www.quintarabio.com

About Transnetyx

Transnetyx, the global leader in automated genotyping solutions, has expanded its portfolio with a comprehensive suite of products and services empowering researchers worldwide to advance discovery efficiently. Headquartered in Cordova, TN, with a European office in Darmstadt, Germany (a-tune), Transnetyx drives innovation, accuracy, and trusted global partnerships. www.transnetyx.com

Media Contact:

Flora Zhang

Marketing Manager (US)

[email protected]

617-971-6980

View original content to download multimedia:https://www.prnewswire.com/news-releases/quintara-biosciences-completes-acquisition-of-laragen-sanger-sequencing-business-strengthening-service-continuity-and-strategic-expansion-in-los-angeles-302584796.html

SOURCE Quintara Biosciences